Galena Biopharma In (GALE) 0.32 $GALE Research Reports

New Post Public Reply Private Reply Replies (0) Message Board

Sep 19, 2016 at 9:07 AM

Galena Biopharma In (GALE) 0.32 $GALE

Research Reports on Biotech Equities -- Galena Biopharma, Mast Therapeutics, Medivation, and Amgen
PR Newswire - Fri Sep 16, 6:35AM CDT
The Biotech industry registered strong gains on Monday, September 12, 2016, with every ETF in the green. Driving stocks higher were surges in M&A deals, dovish comments made by the Fed on policy tightening, and Trump's rising tracking poll results. Today, Stock-Callers.com reviews four equities to see how they fared over the last few trading sessions: Galena Biopharma Inc. (NASDAQ: GALE), Mast Therapeutics Inc. (NYSE MKT: MSTX), Medivation Inc. (NASDAQ: MDVN), and Amgen Inc. (NASDAQ: AMGN). Learn more about these stocks by accessing their free research reports at: http://stock-callers.com/registration
MDVN: 80.87 (-0.18), MSTX: 0.61 (unch), AMGN: 173.52 (+0.56), GALE: 0.32 (-0.01)

Galena Biopharma to Present at the 2016 Aegis Growth Conference
GlobeNewswire - Wed Sep 14, 6:05AM CDT
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will present a corporate update at the 2016 Aegis Growth Conference. The presentation will take place on Thursday, September 22, 2016 at 10:30 a.m. PT at The Encore Hotel in Las Vegas, NV.
GALE: 0.32 (-0.01)

Galena Biopharma Presents Preclinical NeuVax(TM) (nelipepimut-S) Data in Ovarian and Pancreatic Cancer at the Progress in Vaccination Against Cancer (PIVAC) Conference
GlobeNewswire - Tue Sep 13, 8:50AM CDT
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs, today announced that preclinical data from the Company's NeuVax(TM) (nelipepimut-S) program is being presented today at the Progress in Vaccination Against Cancer (PIVAC) Conference in Winchester, UK. NeuVax contains the immunodominant peptide derived from the extracellular region of the HER2 protein, which is expressed in ovarian and pancreatic cancers as well as in breast cancer.
GALE: 0.32 (-0.01)

Galena Biopharma Expands GALE-401 Intellectual Property Protection with Patent Issuance in Japan
GlobeNewswire - Mon Sep 12, 6:05AM CDT
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs, today announced the issuance of a second Japanese Patent (JP Patent #5985719) containing composition and method of use claims for GALE-401, the Company's controlled release version of anagrelide. The patent covers the treatment of patients suffering from myeloproliferative diseases, including myeloproliferative neoplasms (MPNs) such as essential thrombocythemia (ET) and polycythemia vera. The patent provides GALE-401 exclusivity until 2029, not including any patent term extensions.
GALE: 0.32 (-0.01)

Galena Biopharma to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
GlobeNewswire - Fri Sep 09, 6:05AM CDT
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will present a corporate update at the Rodman & Renshaw 18th Annual Global Investment Conference. The presentation will take place on Tuesday, September 13, 2016 at 5:05 p.m. ET at The Lotte New York Palace Hotel, in New York, NY.
GALE: 0.32 (-0.01)

Galena Biopharma (GALE) is Oversold: Can It Recover?
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 8:34AM CDT
Galena Biopharma, Inc. (GALE) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
GALE: 0.32 (-0.01)

New Strong Buy Stocks for August 10th
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 6:42AM CDT
New Strong Buy Stocks for August 10th
NGL: 17.43 (+0.16), CIM: 15.94 (-0.25), INCY: 82.15 (+1.79), GALE: 0.32 (-0.01), ACXM: 26.49 (unch)

Galena Biopharma Reports Second Quarter 2016 Financial Results and Provides a Corporate Update
GlobeNewswire - Tue Aug 09, 3:07PM CDT
-- Advancing GALE-401 (Anagrelide CR) into a pivotal trial for the treatment of essential thrombocythemia
GALE: 0.32 (-0.01)

Aetna (AET) Poised to Beat on Earnings in Q2: Here's Why
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 10:34AM CDT
Our proven model shows that Aetna (AET) is likely to beat on earnings in the second quarter.
ANIP: 64.30 (+0.50), GALE: 0.32 (-0.01), AET: 115.06 (+0.63), HUM: 174.62 (-0.16)

Galena Biopharma (GALE) is Overbought: Is A Drop Coming?
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 8:10AM CDT
Galena Biopharma, Inc. (GALE) has moved higher as of late, but there could definitely be trouble on the horizon for this company
GALE: 0.32 (-0.01)

Biotechnology Stocks Under Review - Eleven Biotherapeutics, Relypsa, Galena Biopharma, and Amgen
PR Newswire - Mon Jun 20, 7:25AM CDT
On Friday, June 17, 2016, the NASDAQ Composite ended the trading session at 4,800.34, down 0.92%; the Dow Jones Industrial Average edged 0.33% lower, to finish at 17,675.16; and the S&P 500 closed at 2,071.22, down 0.33%. However, five out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Eleven Biotherapeutics Inc. (NASDAQ: EBIO), Relypsa Inc. (NASDAQ: RLYP), Galena Biopharma Inc. (NASDAQ: GALE), and Amgen Inc. (NASDAQ: AMGN). Learn more about these stocks by accessing their free trade alerts at:
EBIO: 3.70 (-0.17), RLYP: 31.98 (-0.01), AMGN: 173.52 (+0.56), GALE: 0.32 (-0.01)

Galena Biopharma Presents GALE-401 Combined Safety Data at the European Hematology Association 21st Congress
GlobeNewswire - Mon Jun 13, 6:05AM CDT
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced that combined safety data from the Company's GALE-401 clinical trials were presented at the European Hematology Association 21 Congress. GALE-401 is Galena's controlled release (CR) version of anagrelide for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce elevated platelet counts in patients suffering from myeloproliferative neoplasms (MPNs).
GALE: 0.32 (-0.01)

Galena Biopharma Receives Two Orphan Drug Designations for GALE-301 and GALE-301/GALE-302
GlobeNewswire - Fri Jun 10, 1:46PM CDT
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced the U.S. Food and Drug Administration (FDA) has granted two orphan-drug designations for Galena's two cancer immunotherapy peptides derived from Folate Binding Protein (FBP) for the treatment (including prevention of recurrence) of ovarian cancer: one for GALE-301 (E39), and one for GALE-301 (E39) and GALE-302 (E39'

. In clinical trials, GALE-301, and GALE-301/GALE-302 are combined with the immune adjuvant, granulocyte macrophage-colony stimulating factor (GM-CSF) for the treatment of ovarian cancer in the adjuvant setting.
GALE: 0.32 (-0.01)

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Galena Biopharma, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire - Tue Jun 07, 6:12AM CDT
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Galena Biopharma, Inc. (NASDAQ:GALE).
GALE: 0.32 (-0.01)

Galena Biopharma Presents GALE-301 Phase 1/2a Primary Analysis at the American Society of Clinical Oncology Annual Meeting 2016
GlobeNewswire - Mon Jun 06, 1:00PM CDT
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced the primary analysis from the Company's GALE-301 Phase 1/2a clinical trial at the American Society of Clinical Oncology Annual Meeting 2016. GALE-301 is a cancer immunotherapy consisting of a peptide derived from Folate Binding Protein (FBP) combined with the immune adjuvant, granulocyte macrophage-colony stimulating factor (GM-CSF) for the prevention of cancer recurrence in ovarian and endometrial cancer patients in the adjuvant setting.
GALE: 0.32 (-0.01)

Small Cap Growth Isn't Slowing, Here's Proof
ACCESSWIRE - Thu Jun 02, 8:21AM CDT
NEW YORK, NY / ACCESSWIRE / June 2, 2016 / There's quite a lot of talk about small caps not delivering the sort of growth that they used to over the years but the truth is that many investors who hold this belief are simply not paying attention.
GALE: 0.32 (-0.01)

Galena Biopharma (GALE) in Focus: Stock Moves Up 19.3%
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 7:15AM CDT
Galena Biopharma, Inc. (GALE) shares rose over 19% in the last trading session.
HSKA: 55.33 (-0.25), GALE: 0.32 (-0.01)

Galena Biopharma Receives Fast Track Designation for NeuVax(TM) (nelipepimut-S) PRESENT Clinical Trial
GlobeNewswire - Wed Jun 01, 6:05AM CDT
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced the U.S. Food and Drug Administration (FDA) has designated NeuVax(TM) (nelipepimut-S), combined with recombinant granulocyte macrophage-colony stimulating factor (GM-CSF), as a Fast Track development program for the treatment of patients with early stage, node positive breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, following standard of care. Galena's PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) clinical trial is an international, Phase 3 study to evaluate NeuVax plus GM-CSF versus placebo plus GM-CSF to prevent cancer recurrence.
GALE: 0.32 (-0.01)

Galena Biopharma to Present at the Sachs Associates 2nd Annual Immuno-Oncology BD&L and Investment Forum
GlobeNewswire - Tue May 24, 6:05AM CDT
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will present a corporate update at the Sachs Associates 2 Annual Immuno-Oncology BD&L and Investment Forum. The presentation will take place on Friday, June 3, 2016 at 12:40 p.m. CT at the Hyatt Chicago Magnificent Mile Hotel in Chicago, IL.
GALE: 0.32 (-0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tellus Raises APY to 8.00% Amid Inflation Crunch

Tellus Offers a Boost for Savers Battling Inflation Well, hotshot, if you thought the days of high returns on savings were long gone, tell that to Tellus. This proptech outfit just upped its Reserve Account annual percentage yield (APY) to a juicy 8.00%. That's a damn sight better than the pittance you'll get parking funds elsewhere. Just look at the numbers—consumer...

Aviation Expo Draws Crowds, Revitalizing Future Pilots

Youth Flock to Aviation's Future at Rider Jet Center On a crisp November day in Hagerstown, Maryland, the Rider Jet Center became a hive of ambition and dreams as the 20th Aviation Education & Career Expo unfolded. The whole shebang kicked off like an airport on a holiday weekend, bustling and packed. Over 1,100 students—full of questions, hopes, and the typical teen...

Deadline Nears for Everest Group Class Action Plaintiffs

Everest Group Faces Heavy Litigation Alright, folks, grab your mugs of caffeine and let's dive right into the mess Everest Group, Ltd. has found itself in. The clock is ticking for investors who've taken a punch in the gut between February 8, 2024, and October 27, 2025, courtesy of NYSE: EG. Lawyers are on the chase, and come December 28, 2026, the window to spearhead a...

Qfin Faces Class Action Deadline Amid Regulatory Woes

Hit the Deck: Qfin's Legal Storm Brews When the suits begin to rumble, it’s high time to pull up a seat and watch how these chips fall. If you're parking your funds under NASDAQ:QFIN—heads up! A shareholder rights firm is bringing a class-action lawsuit, and investors perched between March 18 and August 25, 2026, should be ready to jump ship or fight. The Mighty...

Poolwerx Expands in Florida: Matt Feldt's Bold Move

A New Wave in Northeast Florida Bet you didn't expect to hear about pool care while sipping your morning coffee, but here we are. Poolwerx, the heavyweight champion in the pool service world, is pumping up its presence in the Northeast Florida landscape. Guess who’s the man behind this expansion? Matt Feldt, a Navy vet who’s traded in sonar for skimmers, has opened...

Wastewater Treatment Market to Hit $99.56B by 2031

The Changing Face of Wastewater Treatment Here's a whopper to chew on: the wastewater treatment services market ain't your grandfather's playground anymore. No sir, it's a fast-evolving arena aiming to swell to a whopping USD 99.56 billion by 2031. Now, how's that for growth? Mark my words, driven by stringent environmental regulations and thirst for clean water, this...

AI Governance: Banks' Secret to Successful Scaling

AI in Banking: Cautious Steps Forward Banks aren't exactly racing with AI; they're inching forward. With AI agents entering the picture, you'd think the buzz would be about groundbreaking deployments. Instead, the story here is more about banks holding their cards close to the vest. Agentic AI, with its ability to plan and act without a human babysitter at every step, is...

Global Youth Co-Creation Plan Inspires Deep Living

Rediscovering Authenticity in a Fast-Paced World In a world obsessed with snappy content and instant fame, it's refreshing to see an initiative like the Global Youth Image Co-creation Plan take center stage. Unveiled at the third Hong Kong Night, the plan isn't just another flash in the pan. No, it's a call—practically a rallying cry—for young creators worldwide to...

POWERCHINA's Clean Energy Initiatives at COP31 Spotlighted

A Global Push for Clean Energy: POWERCHINA's Role Picture this: a bustling global scene at the United Nations Climate Change Conference, COP31, in Antalya, with leaders huddling over the future of our planet's energy. Meanwhile, Power Construction Corporation of China (POWERCHINA) is out there in the trenches, muscling through the monumental task of turning ambitious...

Lululemon Lawsuit Looms: Investors Face Key Decisions

Seems Lululemon just tripped on its yoga mat. When a company like Lululemon Athletica, Inc (NASDAQ:LULU) sees a 17.38% slide in stock, every savvy investor knows there's more beneath the surface. Squarely in the crosshairs of a securities fraud class action, the brand synonymous with upscale athleisure faces harsh scrutiny. And the deadline's ticking—even the suits know...